Medical marijuana in the United States has reached a major turning point, with the federal government's recent reclassification of the substance from Schedule I to Schedule III. This unprecedented move acknowledges the therapeutic potential of cannabis and sets the stage for broad regulatory and business changes. The decision is being heralded as a groundbreaking shift for the medical cannabis industry, patient advocates, and policymakers, though it stops short of full legalization. Here’s what this reclassification means and what challenges still lie ahead.

What the reclassification entails

Under the federal Controlled Substances Act (CSA), a Schedule III classification applies to substances with "moderate to low potential for physical and psychological dependence," as opposed to Schedule I, which is reserved for drugs that are deemed to have "no currently accepted medical use and a high potential for abuse." This marks the first time in over fifty years that the federal government has formally acknowledged marijuana’s medical value.

According to the federal order, natural Delta-9 tetrahydrocannabinol (THC) can now be classified as a Schedule III substance, but with critical limitations. Most notably, only medical marijuana that is regulated under state medical programs or marijuana included in FDA-approved drug products falls under this new classification. Synthetic cannabinoids or marijuana classified for adult-use recreational markets remain outside the scope of the rescheduling.

Removing the 280E tax penalty

For cannabis businesses operating under state-defined medical marijuana licenses, the change has significant financial implications. Crucially, it removes the restrictions imposed by Section 280E of the U.S. Internal Revenue Code. This federal tax penalty had previously prohibited Schedule I and II drug operators from deducting normal business expenses. Now, medical marijuana businesses adhering to Schedule III guidelines can access these standard tax deductions, potentially improving profitability after years of restrictive taxation.

Pathway to DEA registration

The reclassification also establishes a framework for state-licensed medical cannabis businesses to register with the Drug Enforcement Administration (DEA). Registration is key for legitimizing previously unregulated sectors of the industry at the federal level. Businesses that opt into the DEA's closed-loop registration system will be required to comply with rigorous inventory control measures, import/export regulations, and other compliance protocols. Legal practitioners familiar with cannabis-adjacent industries, such as psychedelics, have emphasized their readiness to help companies navigate this complex new landscape.

According to participants in a webinar hosted by the prominent law firm Vicente, the DEA application forms to secure registration as a medical cannabis business are already available. Applicants have 60 days to submit their paperwork. While becoming a DEA-registered operator opens doors to participating in federally legitimized operations, businesses will need to weigh the potential trade-offs, such as stricter regulatory oversight and the costs of compliance.

Diverging pathways for state and federal licensing

The reclassification establishes two distinct pathways for medical cannabis businesses: those that register with the DEA and those that remain exclusively state-regulated. DEA-registered entities will be permitted to operate within their closed-loop operational ecosystems, where interactions are strictly limited to other registered entities. State-licensed operators who opt out of DEA registration, meanwhile, may continue under their respective state programs, but they will not benefit from the protections afforded by federal classification.

An additional bifurcation arises in states offering hybrid licenses that extend to both medical and adult-use cannabis, such as Colorado, Oregon, Nevada, and Washington. For these businesses, segregation of inventory and sales streams is essential to maintaining compliance under federal law. Companies with dual-license frameworks will need to exercise caution, particularly as federal agencies remain vigilant about treaty compliance and state-federal alignment.

The role of the FDA and future regulatory challenges

Although the DEA rescheduling is groundbreaking, cannabis remains subject to the purview of the U.S. Food and Drug Administration (FDA), particularly when used for medical purposes. Under federal law, medical marijuana products, as drugs, must meet FDA approval for safety and efficacy. Historically, the FDA has not approved new drug applications for botanical marijuana, and the agency has long maintained a cautious enforcement posture regarding medical cannabis.

Legal experts suggest that the FDA is unlikely to pivot to aggressive enforcement following rescheduling. Instead, the agency may focus on closely monitoring rescheduled cannabis activities for compliance while continuing its historically hands-off approach. However, it remains unclear whether FDA-approved clinical trials will eventually catalyze broader federal acceptance of cannabis-based medicines.

Implications for interstate commerce

Interstate commerce poses yet another unresolved challenge. Even under the new classification, marijuana cannot cross state lines without legal justification under both DEA and FDA authority. The Controlled Substances Act prohibits interstate operations unless cleared by all regulatory bodies involved, further complicated by individual state laws banning interstate cannabis trade.

The dormant commerce clause of the U.S. Constitution could eventually come into play to challenge these trade restrictions. But until clear federal guidance emerges, businesses remain restricted to operating intrastate markets, even under DEA registration—a limitation that could hinder the national economy-of-scale opportunities for many operators.

A victory for patient advocacy

Advocates who have long worked to carve pathways for medically approved cannabis underscore the human impact of this reclassification. Patients with cancer, AIDS, or other debilitating illnesses have faced barriers to marijuana’s medicinal use due to criminalization under Schedule I. Some have been denied transplants, had benefits stripped, or been pushed out of public housing for receiving treatment. Legal experts agree that acknowledging marijuana’s therapeutic value at the federal level represents a historic step toward improving access and patient dignity.

What comes next?

The DEA and stakeholders will convene hearings in late June to deliberate whether the Schedule III reclassification should be expanded further to include recreational cannabis. The pathway to full reclassification will not be without its hurdles, as federal agencies navigate compliance with the Single Convention on Narcotic Drugs, an international treaty that shapes drug control policy.

While this reclassification is far from the final word on federal cannabis regulation, it highlights a clear evolution in the government’s stance on marijuana policy. For medical cannabis businesses, patients, and advocates, it marks the beginning of a new era of legitimacy and access, even as questions about adult-use markets and interstate commerce remain unresolved. The broader industry’s future remains in flux, but for now, the move to Schedule III is a victory worth celebrating.